Sex-based differences in vascular function

Women's Health

Volumn 6, Issue 5, 2010, Pages 737-752

  Miller, V M ^a  

^a MAYO CLINIC   (United States)

Author keywords

cardiovascular disease; endothelial cells; estrogen; genetic polymorphisms; Kronos Early Estrogen Prevention study; testosterone; Womens Health Initiative

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; AROMATASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOL METHYLTRANSFERASE; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; PLACEBO; PROSTACYCLIN; SEX HORMONE; SULFOTRANSFERASE 1A1; TESTOSTERONE; THROMBOXANE;

ATHEROSCLEROSIS; AUTOSOME; CAG REPEAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG RESPONSE; GENE EXPRESSION; GENETIC POLYMORPHISM; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPERTENSION; NONHUMAN; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SRY GENE; STEROID METABOLISM; X CHROMOSOME; Y CHROMOSOME;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PROCESSES; CHROMOSOMES, HUMAN, X; CHROMOSOMES, HUMAN, Y; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; RISK FACTORS; SEX CHARACTERISTICS;

EID: 77957739600     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.53     Document Type: Review

References (200)

1. Lloyd-Jones D, Adams RJ, Brown TM et al.: Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121(7), 46-215 (2010).
2. Gochfeld M: Sex-gender research sensitivity and healthcare disparities. J. Womens Health 19, 189-194 (2010).
3. Shaw LJ, Bairey Merz CN, Pepine CJ et al.: Insights from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study: part i: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J. Am. Coll. Cardiol. 47, 4-20 (2006).
4. Bairey Merz CN, Shaw LJ, Reis SE et al.: Insights from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study: part ii: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J. Am. Coll. Cardiol. 47, 21-29 (2006).
5. Barber DA, Burnett JC Jr, Miller VM: Gender differences in relaxations evoked by C-type natriuretic peptide in porcine coronary arteries. Endothelium 2, 2 (1995).
6. Barber DA, Miller VM: Gender differences in endothelium-dependent relaxations do not involve NO in porcine coronary arteries. Am. J. Physiol. 273, 2325-2332 (1997).
7. Brandes RP, Mugge A: Gender differences in the generation of superoxide anions in the rat aorta. Life Sci. 60, 391-396 (1997).
8. Lawrence JB, Leifer DW, Moura GL et al.: Sex differences in platelet adherence to subendothelium: relationship to platelet function tests and hematologic variables. Am. J. Med. Sci. 309, 201-207 (1995).
9. Maddox YT, Falcon JG, Ridinger M, Cunard CM, Ramwell PW: Endothelium-dependent gender differences in the response of the rat aorta. J. Pharmacol. Exper. Ther. 240, 392-395 (1987).
10. Nathan L, Pervin S, Singh R, Rosenfeld M, Chaudhuri G: Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo. Possible mechanisms for gender differences in atherosclerosis. Circ. Res. 85, 377-385 (1999).
11. Lamping KG, Faraci FM: Role of sex differences and effects of endothelial NO synthase defciency in responses of carotid arteries to serotonin. Arterioscler. Thromb. Vasc. Biol. 21, 523-528 (2001).
12. + and ecNOS activity. Am. J. Physiol. Heart Circ. Physiol. 276, 961-969 (1999).
13. Regitz-Zagrosek V, Lehmkuhl E, Lehmkuhl HB, Hetzer R: Gender aspects in heart failure. Pathophysiology and medical therapy Arch. Mal. Coeur Vaiss. 97, 899-908 (2004).
14. Leung J, Jayachandran M, Kendall-Thomas J et al.: Pilot study of sex differences in chemokine/cytokine markers of atherosclerosis in humans. Gend. Med. 5 44-52 (2008).
15. Fortes ZB, Nigro D, Scivoletto R, Carvalho MHC: Infuence of sex on the reactivity to endothelin-1 and noradrenaline in spontaneously hypertensive rats. Clin. Exp.Hypertens. A 13(5), 807-816 (1991).
16. Vincent M, Kaiser MA, Orea V, Lodwick D, Samani NJ: Hypertension in the spontaneously hypertensive rat and the sex chromosomes. Hypertension 23, 161-166 (1994).
17. Muller M, van den Beld AW, Bots ML et al.: Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109, 2074-2079 (2004).
18. Narkiewicz K, Phillips BG, Kato M et al.: Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 45, 522-525 (2005).
19. Duckles SP, Miller VM: Hormonal modulation of endothelial no production. Pfugers Arch. Eur. J. Physiol. 459, 841-851 (2010).
20. Bush TL, Barrett-Connor E: Noncontraceptive estrogen use and cardiovascular disease. Epidemiol. Rev. 7, 89-104 (1985).
21. Bush TL, Cowan LD, Barrett-Connor E et al.: Estrogen use and all-cause mortality preliminary results from the lipid research clinics program follow-up study. JAMA 249, 903-906 (1983).
22. Bush TL, Barrett-Connor E, Cowan LD et al.: Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the lipid research clinics program follow-up study. Circulation 75, 1102-1109 (1987).
23. Adams MR, Clarkson TB, Kaplan JR, Koritnik DR: Experimental evidence in monkeys for benefcial effects of estrogen on coronary artery atherosclerosis. Transplant Proc. 21, 3662-3664 (1989).
24. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein KP: Remodeling of coronary arteries in human and nonhuman primates. J. Am. Med. Assoc. 271, 289-294 (1994).
25. Arnold AP: Sex chromosomes and brain gender. Nat. Rev. Neurosci. 5, 701-708 (2004).
26. Arnold AP, Chen X: What does the 'four core genotypes' mouse model tell us about sex differences in the brain and other tissues? Front Neuroendocrinol. 30, 1-9 (2009).
27. Becker JB, Arnold AP, Berkley KJ et al.: strategies and methods for research on sex differences in brain and behavior. Endocrinology 146, 1650-1673 (2005).
28. Liu M, Oyarzabal EA, Yang R, Murphy SJ, Hurn PD: A novel method for assessing sex-specifc and genotype-specifc response to injury in astrocyte culture. J. Neurosci. Methods 171, 214-217 (2008).
29. Wald C, Wu C: Of mice and women: the bias in animal models. Science 327, 1571-1572 (2010).
30. Zucker I, Beery A: Males still dominate animal studies. Nature 465(7299), 690 (2010).
31. Wizemann TM, Pardue ML: Exploring the Biological Contributions to Human Health: Does Sex Matter? Board on Health Sciences policy Institute of Medicine, Washington, DC, USA (2001).
32. Turner ME, Farkas J, Dunmire J, Ely D, Milsted A: Which sry locus is the hypertensive Y chromosome locus? Hypertension 53, 430-435 (2009).
33. Laurent P, Albaladejo P, Blacher J et al.: Heart rate and pulse pressure amplifcation in hypertensive subjects. Am. J. Hypertens. 16, 363-370 (2003).
34. Reyes D, Lew SQ, Kimmel PL: Gender differences in hypertension and kidney disease. Med. Clin. North Am. 89, 613-630 (2005).
35. Caplea A, Seachrist D, Daneshvar H, Dunphy G, Ely D: Noradrenergic content and turnover rate in kidney and heart shows gender and strain differences. J. Appl. Physiol. 92, 567-571 (2002).
36. Reckelhoff JF: Gender differences in the regulation of blood pressure. Hypertension 37, 1199-1208 (2001).
37. Avner P, Heard E: X-chromosome inactivation: counting, choice and initiation. Nat. Rev. Genet. 2, 59-67 (2001).
38. Van PL, Bakalov VK, Zinn AR, Bondy CA: Maternal X chromosome, visceral adiposity and lipid profle. JAMA 295, 1373-1374 (2006).
39. Singh ND, Petrov DA: Evolution of gene function on the X chromosome versus the autosomes. Genome Dyn. 3, 101-118 (2007).
40. Hersberger M MJ, Funke H, Marti-Jaun J et al.: The CAG repeat polymorhism in the androgen receptor gene is associated with HDL-cholesterol but not with coronary atherosclerosis or myocardial infarction. Clin. Chem. 51, 1110-1115 (2005).
41. Alevizaki M CA, Garofallaki M, Sarika HL et al.: The androgen receptor gen CAG polymorhphism is associated with the severity of coronary artery disease in men. Clin. Endocrinol. (Oxf.) 59, 749-755 (2003).
42. Zitzmann M, Brune M, Kornmann B et al.: The CAG repeart polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J. Clin. Endocrinol. Metab. 86, 4867-4873 (2001).
43. Zitzmann M, Nieschlag E: The CAG repeat polymorphism within the androgen receptor gene and maleness. Int. J. Androl. 26, 76-83 (2003). (Pubitemid 36408236)
44. Min Jiang IH: Polymorphisms in androgen and estrogen receptor genes: effects on male aging. Exp. Gerontol. 39, 1603-1611 (2004).
45. Pausova Z, Abrahamowicz M, Mahboubi A et al.: Functional variation in the androgen-receptor gene is associated with visceral adiposity and blood pressure in male adolescents. Hypertension 55, 706-714 (2010).
46. Van Nieuwerburgh F, Stoop D, Cabri P et al.: Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. Gynecol. Endocrinol. 24, 669-673 (2008).
47. Ferk P, Perme MP, Teran N, Gersak K: Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome. Fertil. Steril. 90, 860-863 (2008).
48. Liu Q, Hong J, Cui B et al.: Androgen receptor gene CAG(n) trinucleotide repeats polymorphism in Chinese women with polycystic ovary syndrome. Endocrine 33, 165-170 (2008).
49. Wild RA, Carmina E, Diamanti-Kandarakis E et al.: Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-POS) Society. J. Clin. Endocrinol. Metab. 95, 2038-2049 (2010).
50. Shah NA, Antoine HJ, Pall M et al.: Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 1939-1945 (2008).
51. Yang X, Schadt EE, Wang S et al.: Tissue-specifc expression and regulation of sexually dimorphic genes in mice. Genome Res. 16, 995-1004 (2006).
52. Rana BK, Insel PA, Payne SH et al.: Population-based sample reveals gene-gender interactions in blood pressure in white americans. Hypertension 49, 96-106 (2007).
53. Regitz-Zagrosek V: Therapeutic implications of the gender-specifc aspects of cardiovascular disease. Nat. Rev. Drug Discov. 5, 425-438 (2006).
54. Nieuwenhoven L, Klinge I: Scientifc excellence in applying sex-and gender-sensitive methods in biomedical and health research. J. Womens Health 19, 313-321 (2010).
55. Melloni C, Berger JS, Wang TY et al.: Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ. Cardiovasc. Qual. Outcomes 3(2), 135-42 (2010).
56. Schnoes KK, Jaffe IZ, Iyer L et al.: Rapid recruitment of temporally distinct vascular gene sets by estrogen. Mol. Endocrinol. 22, 2544-2556 (2008).
57. Enmark E, Gustafsson JA: Oestrogen receptors-an overview. J. Intern. Med. 246, 133-138 (1999).
58. Sudhir K, Chou TM, Messina LM et al.: Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 349, 1146-1147 (1997).
59. Sudhir K, Chou TM, Chatterjee K et al.: Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 96, 3774-3777 (1997).
60. Gavin KM, Seals DR, Silver AE, Moreau KL: Vascular endothelial estrogen receptor α is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J. Clin. Endocrinol. Metab. 94, 3513-3520 (2009).
61. Christian R, Liu P, Harrington S et al.: Intimal estrogen receptor (ER) β, but not ERα expression, is correlated with coronary calcifcation and atherosclerosis in pre-and postmenopausal women. J. Clin. Endocrinol. Metab. 91, 2713-2720 (2006).
62. Zhu Y, Bian Z, Lu P et al.: Abnormal vascular function and hypertension in mice defcient in estrogen receptor β. Science 295, 505-508 (2002).
63. Peter I SA, Vasan RS, Zucker DR et al.: Association of estrogen receptor β gene polymorhisms with left ventricular mass and wall thickness in women. Am. J. Hypertens. 18, 1388-1395 (2005).
64. Traupe T, Stettler CD, Li H et al.: Distinct roles of estrogen receptors α and β mediating acute vasodilation of epicardial coronary arteries. Hypertension 49, 1364-1370 (2007).
65. Peter I, Kelley-Hedgepeth A, Fox CS et al.: Variation in estrogen-related genes associated with cardiovascular phenotypes and circulating estradiol, testosterone, and dehydroepiandrosterone sulfate levels. J. Clin. Endocrinol. Metab. 93, 2779-2785 (2008).
66. Rexrode KM, Ridker PM, Hegener HH et al.: Polymorphisms and haplotypes of the estrogen receptor-β gene (ESR2) and cardiovascular disease in men and women. Clin. Chem. 53, 1749-1756 (2007).
67. Sowers MR, Wilson AL, Kardia SR, Chu J, McConnell DS: CYP1A1 and CYP1B1 polymorphisms and their association with estradiol and estrogen metabolites in women who are premenopausal and perimenopausal. Am. J. Med. 119, 44-51 (2006).
68. Shearman AM, Cupples LA, Demissie S et al.: Association between estrogen receptor α gene variation and cardiovascular disease. JAMA 290, 2263-2270 (2003).
69. Peter I SA, Zucker DR, Schmid CH et al.: Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study J. Hyperten. 23, 2193-2200 (2005).
70. Demissie S CL, Shearman AM, Gruenthal KM et al.: Estrogen receptor-ct variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. Atherosclerosis 185, 210-218 (2006).
71. Schuit S, Oei HS, Witteman J et al.: Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 291, 2969-2977 (2004). (Pubitemid 38802686)
72. Herrington DM, Howard TD, Hawkins GA et al.: Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346, 967-974 (2002).
73. Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR: Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women's Health Across the Nation (SWAN). Am. J. Med. 119, S61-S68 (2006).
74. O'Lone R, Knorr K, Jaffe IZ et al.: Estrogen receptors α and β mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol. Endocrinol. 21, 1281-1296 (2007).
75. Sowers MF, Wilson AL, Kardia SR, Chu J, Ferrell RE: Aromatase Gene (CYP 19) polymorphisms and endogenous androgen concentrations in a multiracial/multiethnic, multisite study of women at midlife. Am. J. Med. 119, 523-530 (2006).
76. Lo JC, Zhao X, Scuteri A, Brockwell S, Sowers MR: The association of genetic polymorphisms in sex hormone biosynthesis and action with insulin sensitivity and diabetes mellitus in women at midlife. Am. J. Med. 119, 69-78 (2006).
77. Peter I, Kelley-Hedgepeth A, Huggins GS et al.: Association between arterial stiffness and variations in oestrogen-related genes. J. Hum. Hypertens. 23, 636-644 (2009).
78. Cavalieri EL, Stack DE, Devanesan PD et al.: Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc. Natl Acad. Sci. USA 94, 10937-10942 (1997).
79. Worda C, Sator MO, Schneeberger C et al.: Infuence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum. Reprod. 18, 262-266 (2003).
80. Hagen K, Stovner LJ, Skorpen F, Pettersen E, Zwart JA: The impact of the catechol-O-methyltransferase Val 158Met polymorphism on survival in the general population-the HUNT study BMC Med. Genet. 19(8), 34 (2007).
81. Tempfer CB, Riener EK, Hefer LA, Huber JC, Muendlein A: DNA microarray-based ana lysis of single nucleotide polymorphisms may be useful for assessing the risks and benefts of hormone therapy. Fertil. Steril. 82, 132-137 (2004).
82. Hebbring SJ, Adjei AA, Baer JL et al.: Human SULT1A1 gene: copy number differences and functional implications. Hum. Mol. Genet. 16, 463-470 (2007).
83. Zhu BT: Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3, 321-349 (2002).
84. Hodges YK, Tung L, Yan X-D et al.: Estrogen receptors α and β. Prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects. Circulation 101, 1792-1798 (2000).
85. Barton M, Meyer MR, Haas E: Hormone replacement therapy and atherosclerosis in postmenopausal women: does aging limit therapeutic benefts? Arterioscler. Thromb. Vasc. Biol. 27, 1669-1672 (2007).
86. Liu PY, Christian RC, Ruan M, Miller VM, Fitzpatrick LA: Correlating androgen and estrogen steroid receptor expression with coronary calcifcation and atherosclerosis in men without known coronary artery disease. J. Clin. Endocrinol. Metab. 90, 1041-1046 (2005).
87. Okano H, Jayachandran M, Yoshikawa A, Miller VM: Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. J. Cardiovasc. Pharmacol. 47, 621-628 (2006).
88. Rzewuska-Lech E, Jayachandran M, Fitzpatrick LA, Miller VM: Differential effects of 17β-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. Am. J. Physiol. Endocrinol. Metab. 289, E105-E112 (2005).
89. Ihionkhan CE, Chambliss KL, Gibson LL et al.: Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ. Res. 91, 814-820 (2002).
90. Gonzales RJ, Ansar S, Duckles SP, Krause DN: Androgenic/estrogenic balance in the male rat cerebral circulation: metabolic enzymes and sex steroid receptors. J. Cereb. Blood Flow Metab. 27, 1841-1852 (2007).
91. Olson MB, Kelsey SF, Matthews K et al.: Symptoms, myocardial ischaemia and quality of life in women: results from the NHLBI-sponsored WISE study. Eur. Heart J. 24, 1506-1514 (2003).
92. Kuiper GG, Carlsson B, Grandien K et al.: Comparison of the ligand binding specifcity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870 (1997). (Pubitemid 27089735)
93. McCredie RJ, McCrohon JA, Turner L et al.: Vascular reactivity is impaired in genetic females taking high-dose androgens. J. Am. Coll. Cardiol. 32, 1331-1335 (1998).
94. New G, Timmins KL, Duffy SJ et al.: Long-term estrogen therapy improves vascular function in male to female transsexuals. J. Am. Coll. Cardiol. 29, 1437-1444 (1997).
95. Toorians AW, Thomassen MC, Zweegman S et al.: Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J. Clin. Endocrinol. Metab. 88, 5723-5729 (2003).
96. Fortin CJ, Klein T, Messmore HL, O'Connell JB: Myocardial infarction and severe thromboembolic complications. As seen in an estrogen-dependent transsexual. Arch. Intern. Med. 144, 1082-1083 (1984).
97. Resmini E, Casu M, Patrone V et al.: Sympathovagal imbalance in transsexual subjects. J. Endocrinol. Invest. 31, 1014-1019 (2008).
98. Elamin M, Garcia M, Murade M, Erwin P, Montori V: Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin. Endocrinol. (Oxf) 72, 1-10 (2010).
99. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G et al.: Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fbrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler. Thromb. Vasc. Biol. 17, 3071-3078 (1997).
100. Ho JY-P, Chen M-J, Sheu WH-H et al.: Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Human Reprod. 21, 2715-2720 (2006).
101. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T et al.: Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fbrinolysis, infammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85, 619-625 (2001).
102. Santen RJ, Allred DC, Ardoin SP et al.: Postmenopausal hormone therapy: an endocrine society scientifc statement. J. Clin. Endocrinol. Metab. 95(Suppl. 1), S1-S66 (2010).
103. Orshal JM, Khalil RA: Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, 233-249 (2004).
104. Miller VM, Duckles SP: Vascular actions of estrogens: functional implications. Pharmacol. Rev. 60, 210-241 (2008).
105. Duckles SP, Krause DN, Stirone C, Procaccio V: Estrogen and mitochondria: a new paradigm for vascular protection? Mol. Interv. 6, 26-35 (2006).
106. Levin ER: G Protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology 150, 1563-1565 (2009).
107. Moriarty K, Kim KH, Bender JR: Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147, 5557-5563 (2007).
108. Meyer MR, Haas E, Prossnitz ER, Barton M: Nongenomic regulation of vascular cell function and growth by estrogen. Mol. Cell Endocrinol. 308, 9-16 (2009).
109. Sudhir K, Komesaroff PA: Cardiovascular actions of estrogens in men. J. Clin. Endocrinol. Metab. 84, 3411-3415 (1999).
110. Bunck MC, Toorians AW, Lips P, Gooren LJ: The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals. Eur. J. Endocrinol. 154, 569-575 (2006).
111. Williams JK, Adams MR, Klopfenstein HS: Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81, 16 80-1687 (1990).
112. Williams JK, Adams MR, Herrington DM, Clarkson TB: Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 20, 452-457 (1992).
113. Williams SP, Shackelford DP, Iams SG, Mustafa SJ: Endothelium-dependent relaxation in estrogen-treated spontaneously hypertensive rats. Eur. J. Pharmacol. 145, 205-207 (1988).
114. 2+] effux from female porcine coronary arterial smooth muscle. Am. J. Physiol. (Heart Circ Physiol) 45, H926-H934 (1999).
115. White RE, Darkow DJ, Falvo Lang JL: Estrogen relaxes coronary arteries by opening BK channels through a cGMP-dependent mechanism. Circ. Res. 77, 936-942 (1995).
116. Farhat MY, Wolfe R, Bargas R, Foegh ML, Ramwell PW: Effect of testosterone treatment on vasoconstrictor response of left anterior descending coronary artery in male and female pigs. J. Cardiovasc. Pharmacol. 25, 495-500 (1995).
117. Herman SM, Robinson JT, McCredie RJ et al.: Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler. Thromb. Vasc. Biol. 17, 2004-2009 (1997).
118. Yu J, Akishita M, Eto M et al.: Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/Akt pathway Endocrinology 151, 1822-1828 (2010).
119. Webb CM, McNeill JG, Hayward CS, deZeigler D, Collins P: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100, 1690-1696 (1999). (Pubitemid 29485250)
120. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P: Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91, 1154-1160 (1995).
121. Chatrath R, Ronningen KL, Severson SR et al.: Endothelium-dependent responses in coronary arteries are changed with puberty in male pigs. Am. J. Physiol. Heart Circ. Physiol. 285, 1168-1176 (2003).
122. Koledova VV, Khalil RA: Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev. Cardiovasc. Ther. 5, 777-789 (2007).
123. Yang E, Jeon SB, Baek I et al.: 17β-estradiol attenuates vascular contraction through inhibition of RhoA/Rho kinase pathway Naunyn Schmiedebergs Arch. Pharmacol. 380, 35-44 (2009).
124. Jacob J, Sebastian KS, Devassy S et al.: Membrane estrogen receptors: genomic actions and post transcriptional regulation. Mol. Cell Endocrinol. 246, 34-41 (2006).
125. O'Lone R, Knorr K, Jaffe IZ et al.: Estrogen receptors α and β mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol. Endocrinol. 21, 1281-1296 (2007).
126. Wierman ME: Sex steroid effects at target tissues: mechanism of action. Adv. Physiol. Educ. 31, 26-33 (2007).
127. Meyer M, Haas E, Barton M: Gender differences of cardiovascular disease, new persepctives for estrogen signaling. Hypertension 47, 1019-1026 (2006).
128. Prossnitz ER, Barton M: Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat. 89, 89-97 (2009).
129. Gorodeski GI: Estrogen decrease in tight junctional resistance involves matrix-metalloproteinase-7-mediated remodeling of occludin. Endocrinology 148, 218-231 (2007).
130. Li GH, Chen YF, Kelpke SS, Oparil S, Thompson JA: Estrogen attenuates integrin-β(3)-dependent adventitial fbroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. Circulation 101, 2949-2955 (2000).
131. Lewandowski KC, Komorowski J, Mikhalidis DP et al.: Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women. J. Clin. Endocrinol. Metab. 91, 31 23-3130 (2006).
132. Hu P, Greendale GA, Palla SL et al.: The effects of hormone therapy on the markers of infammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the Postmenopausal Estrogen Progestin Intervention (PEPI) trial. Atherosclerosis 185, 347-352 (2006).
133. Hwang J, Hodis HN, Hsiai TK, Asatryan L, Sevanian A: Role of annexin II in estrogen-induced macrophage matrix metalloproteinase-9 activity: the modulating effect of statins. Atherosclerosis 189, 76-82 (2006).
134. Losordo DW, Isner JM: Estrogen and angiogenesis: a review. Arterioscler. Thromb. Vasc. Biol. 21, 6-12 (2001).
135. Fadini GP, de Kreutzenberg S, Albiero M et al.: Gender differences in endothelial progenitor cells and cardiovascular risk profle: the role of female estrogens. Arterioscler. Thromb. Vasc. Biol. 28, 997-1004 (2008).
136. Hamada H, Kim MK, Iwakura A et al.: Estrogen receptors α and β mediate contribution of bone marrow-derived endothelial progenitor cells to functional recovery after myocardial infarction. Circulation 114, 2261-2270 (2006).
137. Bulut D, Albrecht N, Imohl M et al.: Hormonal status modulates circulating endothelial progenitor cells. Clin. Res. Cardiol. 96, 258-263 (2007).
138. Imanishi T, Hano T, Nishio I: Estrogen reduces angiotensin II-induced acceleration of senescence in endothelial progenitor cells. Hypertens. Res. 28, 263-271 (2005). (Pubitemid 40812612)
139. Imanishi T, Hano T, Nishio I: Estrogen reduces endothelial progenitor cell senescence through augmentation of telomerase activity J. Hyperten. 23, 1699-1706 (2005).
140. Santizo R, Pelligrino DA: Estrogen reduces leukocyte adhesion in the cerebral circulation of female rats. J. Cereb. Blood Flow Metab. 19, 1061-1065 (1999).
141. Xing D, Nozell S, Chen YF, Hage F, Oparil S: Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol. 29, 289-295 (2009).
142. Ball P, Knuppen R: Formation, metabolism, and physiologic importance of catecholestrogens. Am. J. Obstet. Gynecol. 163, 2163-2170 (1990).
143. Paden CM, McEwen BS, Fishman J, Snyder L, DeGroff V: Competition by estrogens for catecholamine receptor binding in vitro. J. Neurochem. 39, 512-520 (1982).
144. Dubey RK, Tofovic SP, Jackson EK: Cardiovascular pharmacology of estradiol metabolites. J. Pharmacol. Exp. Ther. 308, 403-409 (2004).
145. Barchiesi F, Jackson E, Fingerle J et al.: 2-methoxyestradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ. Res. 99, 266-274 (2006).
146. Liu PY, Death AK, Handelsman DJ: Androgens and cardiovascular disease. Endocr. Rev. 24, 313-340 (2003).
147. Phillips GB: Is atherosclerotic cardiovascular disease an endocrinological disorder? The estrogen-androgen paradox. J. Clin. Endocrinol. Metab. 90, 2708-2711 (2005).
148. Mukherjee TK, Dinh H, Chaudhuri G, Nathan L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc. Natl Acad. Sci. USA 99, 4055-4060 (2002).
149. Zhang X, Wang LY, Jiang TY et al.: Effects of testosterone and 17-β-estradiol on TNF-α-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci. 71, 15-29 (2002).
150. Dockery F, Bulpitt C, Agarwal S, Vernon C, Rajkumar C: Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J. Androl. 30, 410-415 (2009).
151. Arain FA, Kuniyoshi FH, Abdalrhim AD, Miller VM: Sex/gender medicine-the biological basis for personalized care in cardiovascular medicine. Circ. J. 73, 1774-1782 (2009).
152. Ross R, Glomset JA: The pathogenesis of atherosclerosis (frst of two parts). N. Engl. J. Med. 295, 369-377 (1976).
153. Ross R, Glomset JA: The pathogenesis of atherosclerosis (second of two parts). N. Engl. J. Med. 295, 420-425 (1976).
154. Jayachandran M, Mukherjee R, Steinkamp T et al.: Differential effects of 17β-estradiol, conjugated equine estrogen and raloxifene on mRNA expression, aggregation and secretion in platelets. Am. J. Physiol. Heart Circ. Physiol. 288, 2355-2362 (2005).
155. Jayachandran M, Karnicki K, Miller RS et al.: Platelet characteristics change with aging: role of estrogen receptor β. J. Gerontol. Biol. Sci. 60, 815-819 (2005).
156. Miller VM, Jayachandran M, Owen WG: Aging, estrogen, platelets and thrombotic risk. Clin. Exp. Pharmacol. Physiol. 34, 814-821 (2007).
157. Jayachandran M, Owen WG, Miller VM: Effects of ovariectomy on aggregation, secretion, and metalloproteinases in porcine platelets. Am. J. Physiol. Heart Circ. Physiol. 284, 1679-1685 (2003).
158. Jayachandran M, Okano H, Chatrath R et al.: Sex-specifc changes in platelet aggregation and secretion with sexual maturity in pigs. J. Appl. Physiol. 97, 1445-1452 (2004).
159. Miller VM, Lewis DA, Barber DA: Gender differences and endothelium-and platelet-derived factors in the coronary circulation. Clin. Exp. Pharmacol. Physiol. 26, 132-136 (1999).
160. Lewis DA, Bracamonte MP, Rud KS, Miller VM: genome and hormones: gender differences in physiology selected contribution: effects of sex and ovariectomy on responses to platelets in porcine femoral veins. J. Appl. Physiol. 91, 2823-2830 (2001).
161. Jimenez JJ, Jy W, Mauro LM et al.: Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb. Res. 109, 175-180 (2003).
162. Boulanger CM, Scoazec A, Ebrahimian T et al.: Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 104, 2649-2652 (2001).
163. Tan KT, Tayebjee MH, Lim HS, Lip GY: Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet. Med. 22, 1657-1662 (2005).
164. Piccin A, Murphy WG, Smith OP: Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 21, 157-171 (2007).
165. Brogan PA, Shah V, Brachet C et al.: Endothelial and platelet microparticles in vasculitis of the young. Arthritis Rheum. 50, 927-936 (2004).
166. Bernal-Mizrachi L, Jy W, Fierro C et al.: Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int. J. Cardiol. 97, 439-446 (2004).
167. Simak J, Gelderman MP, Yu H, Wright V, Baird AE: Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J. Thromb. Haemost. 4, 1296-1302 (2006).
168. Jayachandran M, Litwiller RD, Owen WG et al.: Characterization of blood borne microparticles as markers of premature coronary calcifcation in recently menopausal women. Am. J. Physiol. Heart Circ Physiol 295, 931-938 (2008).
169. Jayachandran M, Litwiller RD, Owen WG, Miller VM: circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric 12, 1-8 (2009).
170. Clarkson TB: Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14, 373-384 (2007).
171. Kalantaridou S, Naka K, Bechlioulis A et al.: Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol. Metab. 17, 101-109 (2006).
172. Rocca W, Grossardt B, Andrade M, Malkasian G, Melton LI: Survival patterns after oophorectomy in premenopausal women: a population-based cohort study Lancet Oncol. 7, 821-828 (2006).
173. Shuster LT, Gostout BS, Grossardt BR, Rocca WA: Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 14, 111-116 (2008).
174. Rossouw JE, Anderson GL, Prentice RL et al.: Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from
175. Grodstein F, Manson JE, Stampfer MJ: Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health 15, 35-44 (2006). (Pubitemid 43192860)
176. Hsia J, Langer RD, Manson JE et al.: Conjugated equine estrogens and coronary heart disease. Arch. Intern. Med. 166, 357-365 (2006).
177. Manson J, Allison M, Rossouw JE et al.: Estrogen therapy and coronary-artery calcifcation. N. Engl. J. Med. 356, 2591-2602 (2007).
178. Vitale C, Mercuro G, Cerquetani E et al.: Time since menopause infuences the acute and chronic effect of estrogens on endothelial function. Arterioscler. Thromb. Vasc. Biol. 28, 348-352 (2008).
179. Harman SM, Brinton EA, Cedars M et al.: KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 8, 3-12 (2005).
180. Canonico M, Oger E, Plu-Bureau G et al.: Hormone therapy and venous thromboembolism among postmenopausal women. Circulation 115, 840-845 (2007).
181. Moreau KL, Donato AJ, Seals DR et al.: Arterial intima-media thickness: site-specifc associations with HRT and habitual exercise. Am. J. Physiol. Heart Circ Physiol 283, H1409-1417 (2002).
182. Hendrix SL, Wassertheil-Smoller S, Johnson KC et al.: Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113, 2425-2434 (2006).
183. Utian WH, Archer DF, Bachmann GA et al.: Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15, 584-603 (2008).
184. Toh S, Hernandez-Diaz S, Logan R, Rossouw JE, Hernan MA: Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? Ann. Intern. Med. 152, 211-217 (2010).
185. Chilvers CED, Knibb RC, Armstrong SJ, Woods KL, Logan RFA: Postmenopausal hormone replacement therapy and risk of acute myocardial infarction-a case control study of women in the East Midlands, UK. Eur. Heart J. 24, 2197-2205 (2003).
186. Weidemann W, Hanke H: Cardiovascular effects of androgens. Cardiovasc. Drug Rev. 20, 175-198 (2002).
187. Sieveking DP, Lim P, Chow RWY et al.: A sex-specifc role for androgens in angiogenesis. J. Exp. Med. 207, 345-352 (2010).
188. Wierman ME, Basson R, Davis SR et al.: Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J. Clin. Endocrinol. Metab. 91, 3697-3710 (2006).
189. Blum A: Treating heart failure with sildenafl. Congest. Heart Fail. 15, 181-185 (2009).
190. Kenny AM, Prestwood KM, Gruman CA et al.: Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. 57, 460-465 (2002).
191. Sowers MR, Jannausch M, Randolph JF et al.: Androgens are associated with hemostatic and infammatory factors among women at the mid-life. J. Clin. Endocrinol. Metab. 90, 6064-6071 (2005).
192. Ling S, Komesaroff PA, Sudhir K: Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr. Metab. Immune Disord. Drug Targets 9, 29-37 (2009).
193. Marts SA, Keitt S: Foreward: A Historical Overview of Advocacy for Research in Sex-Based Biology. In: Principles of Sex-Based Differences in Physiology (34 Edition) Hay M, Miller VM (Eds). Elsevier Publishing Company (2004).
194. Kim AK, Tingen CM, Woodruff TK: Sex bias in trials and treatment must end. Nature 465, 688-689 (2010).
195. Regitz-Zagrosek V, Lehmkuhl E: Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. Herz 30, 356-367 (2005).
196. Lakoski SG, Greenland P, Wong ND et al.: Coronary artery calcium scores and risk for cardiovascular events in women classifed as "low risk" based on framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch. Intern. Med. 167, 2437-2442 (2007).
197. Miller VM, Black DM, Brinton EA et al.: Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J. Cardiovasc. Transl. Res. 2, 228-239 (2009).
198. Mulvagh SL, Behrenbeck T, Lahr BA et al.: Endothelial function and cardiovascular risk stratifcation in menopausal women. Climacteric 13, 45-54 (2010).
199. Shearman AM, Cooper JA, Kotwinski PJ et al.: Estrogen receptor α gene variation is associated with risk of myocardial infarction in more than seven thousand men from fve cohorts. Circ. Res. 98, 590-592 (2006).
200. Shearman AM, Cooper JA, Kotwinski PJ et al.: Estrogen receptor α gene variation and the risk of stroke. Stroke 36, 2281-2282 (2005).